Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Other Operating Expenses (2023 - 2024)

Fate Therapeutics (FATE) has disclosed Other Operating Expenses for 7 consecutive years, with $14.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Operating Expenses changed N/A year-over-year to $14.7 million, compared with a TTM value of $14.7 million through Sep 2025, changed N/A, and an annual FY2024 reading of $14.7 million, up 836.85% over the prior year.
  • Other Operating Expenses was $14.7 million for Q4 2024 at Fate Therapeutics, up from -$2.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $14.7 million in Q4 2024 and bottomed at -$2.0 million in Q1 2023.
  • Average Other Operating Expenses over 3 years is $3.2 million, with a median of -$1000.0 recorded in 2021.